Roar Adelsten
Owns 64.4 percent (privately and via companies). Founder and business developer within the Auxesis group since 2014.
Financial information
Welcome to Auxesis Pharma’s financial section. Here you will find financial information, press releases and information about the ownership structure. Auxesis Pharma develops differentiated drug assets focused on major medical needs in wound care and specialized dermatology.
2016
Founded
800
Shareholders
1(+3)
Patents
Global market potential
Skin pain and irritation category (OTC human)
- The global market for dermal pain relief is expected to reach USD 12.2 billion in 2027, with a growth rate of 5.2% CAGR (2020–2027).
- North America and Europe account for 68% of the global market.
- Asia-Pacific is expected to have the strongest growth rate during 2020–2027 at 6.5% CAGR.
* The distribution in the chart shows regional market share (example data).
Capital
Financing strategy
Current round: VC Growth / Late Seed – Series A Bridge
Use of proceeds
- Clinical development
- Regulatory preparation EU / USA
- Manufacturing scale-up
- Business development and partnerships
Vision
Target state
- Value creation through clinical milestones
- Opportunity for strategic licensing or M&A
- Clear path toward a commercial specialty pharma model
Solid ägarstruktur
Other owners
Other owners collectively hold 35.6 percent and are mainly private individuals and small companies.
Shareholders
Auxesis has approximately 800 shareholders. The source for shareholdings is Euroclear Sweden, which maintains the share register. Figures as of 2025-12-31.
Overview
- Clear regulatory pathway in major markets
- Strong IP strategy around formulation and indication expansion
- Capital-efficient development model
- Multiple strategic routes through partnerships or licensing
Ownership structure
Founders & management65%
Early owners7%
Strategic / industrial0%
Incentive program (ESOP)0%
Free float / others28%
Ledningsgruppen
Experienced leaders with deep expertise in medtech, pharmaceuticals and business development
Peter Åberg
CEO, Drug Development and Sustainability
Peter Åberg leads Auxesis’ strategic development with exceptional expertise in medtech and pharmaceuticals.
Expertise and background
- •CEO and sustainability director in medtech
- •Toxicology and drug safety
- •International leadership experience
Contribution: Drives Auxesis strategically toward sustainable global growth.
Roar Adelsten
Chair of the Board and Founder
Visionary founder with nearly 30 years of experience in the pharmaceutical industry.
Expertise and background
- •Pfizer AS – medical consultant
- •International experience
- •Product development in orthopedics
Contribution: Ensures long-term strategy and innovation.
A well-balanced board and management team
Auxesis Pharma has a well-balanced board and management team representing diverse areas of expertise
Auxesis Pharma Board of Directors
Roar Adelsten
Chair of the Board and Founder
Lars-Olof Peterson
Board Member
Anna Tenstam
Board Member
Auxesis Pharma Management Team
Peter Åberg
CEO, Drug Development and Sustainability
Roar Adelsten
Chair of the Board and Founder
Finansiell kalender
Key dates for financial reports, annual general meetings and other investor events.
Upcoming events
Ongoing offering
The ongoing offering can be subscribed to until 2026-02-13.
Upcoming offering
The upcoming offering can be subscribed to from 2026-02-14.
AGM 2026
Publication of the AGM for the full year 2026.
Finansiella rapporter
Annual Report 2024
June 2025
Annual Report 2023
June 2023
Contact IR
Do you have questions about the company or want to book a meeting with our IR representative?
Investor Relations
+46 (0)8-771 43 00